Cipla today said it has inked an investment agreement with FIL Capital Investments (Mauritius) II Ltd for its consumer healthcare business.

“Cipla Health Ltd and FIL Capital Investments (Mauritius) II Ltd have on November 27 signed an investment agreement,” Cipla said in a regulatory filing.

The investment is subject to approvals from the Foreign Investment Promotion Board and the Competition Commission of India, and the transfer of Cipla’s consumer healthcare business to Cipla Health Ltd, it added.

The company, however, did not disclose the financial details of the agreement.

In July, Cipla’s board had approved an investment by Fidelity Growth Partners India and US-based Fidelity Biosciences, through FIL Capital Investments (Mauritius) II or its affiliates in its recently launched consumer healthcare business.

Through the consumer healthcare business, Cipla has entered the over-the-counter (OTC) healthcare market in India.

Earlier, the Mumbai-based company’s board had approved divestment of its consumer healthcare business to Cipla Health, a wholly-owned subsidiary, by way of a slump sale for a consideration of Rs 10.5 crore.

Indian Consumer Health Care (CHC) is a $4-billion market and is growing at a CAGR of 15 per cent. It is expected to be a $10-billion market by 2020.